查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402096

全球临床肿瘤学下一代定序市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、成长、趋势和预测

Global Clinical Oncology Next Generation Sequencing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

预计到 2030 年，全球临床肿瘤学下一代定序市场的市场规模将从 2022 年的 421.6 万美元达到近 1,406.19 万美元，2023-2030 年研究期间CAGR为 16.25%。

临床肿瘤学次世代定序（NGS）是指先进的基因组定序技术在肿瘤学（癌症照护和治疗）领域的应用。它能够对患者的肿瘤 DNA 或 RNA 进行全面分析，以识别驱动癌症发生、进展和治疗反应的基因改变、突变或变异。

市场动态

下一代定序的技术进步以准确性提高、定序速度更快和成本降低为标誌，推动了其在临床肿瘤学中的采用。向个人化医疗和精准肿瘤学的范式转变扩大了其在分析肿瘤遗传学方面的用途，促进基于个体基因谱的客製化治疗策略。全球癌症发生率不断上升，推动了对 NGS 等先进诊断工具的需求，有助于准确的肿瘤分析和治疗决策。 NGS 在癌症研究、识别新生物标记和治疗标靶以及推动其纳入临床研究和试验中也发挥关键作用。医疗保健提供者越来越多地将基于 NGS 的测试纳入癌症诊断、预后和治疗选择的常规临床实践中。支持性监管环境和既定指南可验证下一代定序应用，确保临床环境的品质和可靠性。技术提供者、製药公司和研究机构之间的伙伴关係和协作促进创新、产品开发和更广泛地获得基于 NGS 的肿瘤学测试。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球临床肿瘤次世代定序市场的各个细分市场进行了包容性评估。临床肿瘤学下一代定序产业的成长和趋势为这项研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲临床肿瘤学下一代定序市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。临床肿瘤新一代定序市场的主要参与者包括Illumina Inc.、Thermo Fisher Scientific、F. Hoffmann-La Roche Ltd.、Agilent Technologies、Myriad Genetics、北京基因组研究所（BGI）、Perkin Elmer、Foundation Medicine、Pacific Bioscience 、Oxford Nanopore Technologies Ltd.、Paradigm Diagnostics、Caris Life Sciences、Partek Inc.、Eurofins Scientific SE、Qiagen NV 本部分包含竞争格局的整体视图，其中包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：临床肿瘤学下一代定序 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按技术分類的市场吸引力分析
    • 依工作流程进行市场吸引力分析
    • 市场吸引力分析：依应用分类
    • 按最终用途分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球临床肿瘤学下一代定序市场分析：按技术分类

  • 依技术概述
  • 历史和预测数据
  • 依技术分析
  • 全基因组定序
  • 全外显子定序
  • 标靶定序和重定序

第 6 章：全球临床肿瘤学下一代定序市场分析：依工作流程

  • 按工作流程概述
  • 历史和预测数据
  • 按工作流程分析
  • NGS预测序
  • NGS定序
  • NGS数据分析

第 7 章：全球临床肿瘤学下一代定序市场分析：按应用分类

  • 概述：按应用
  • 历史和预测数据
  • 分析：按应用
  • 筛检（散发性癌症、遗传性癌症）
  • 伴随诊断
  • 其他诊断

第 8 章：全球临床肿瘤学下一代定序市场分析：按最终用途分类

  • 按最终用途分類的概述
  • 历史和预测数据
  • 按最终用途分析
  • 医院
  • 诊所
  • 实验室

第 9 章：全球临床肿瘤学下一代定序市场分析：按地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：临床肿瘤学下一代定序公司的竞争格局

  • 临床肿瘤学下一代定序市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 公司股份分析
  • 市场集中度
  • Illumina Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Thermo Fisher Scientific
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • F. Hoffmann-La Roche Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Agilent Technologies
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Myriad Genetics
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Beijing Genomics Institute (BGI)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Perkin Elmer
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Foundation Medicine
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Pacific Bioscience
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Oxford Nanopore Technologies Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Paradigm Diagnostics
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Caris Life Sciences
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Partek Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Eurofins Scientific SE
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Qiagen NV
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

Product Code: VMR112112976

The global demand for Clinical Oncology Next Generation Sequencing Market is presumed to reach the market size of nearly USD 1406.19 MN by 2030 from USD 421.6 MN in 2022 with a CAGR of 16.25% under the study period 2023 - 2030.

Clinical oncology next generation sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology (cancer care and treatment). It enables the comprehensive analysis of a patient's tumor DNA or RNA to identify genetic alterations, mutations, or variations that drive cancer development, progression, and response to treatments.

MARKET DYNAMICS

Technological advancements in next generation sequencing, marked by enhanced accuracy, faster sequencing, and reduced costs, drive its adoption in clinical oncology. The paradigm shift towards personalized medicine and precision oncology amplifies its use for analyzing tumor genetics, facilitating tailored treatment strategies based on individual genetic profiles. The escalating incidence of cancer globally fuels the demand for advanced diagnostic tools like NGS, aiding accurate tumor profiling and treatment decisions. NGS also plays a pivotal role in cancer research, identifying new biomarkers and therapeutic targets, and driving its incorporation into clinical studies and trials. Healthcare providers increasingly integrate NGS-based tests into routine clinical practice for cancer diagnosis, prognosis, and treatment selection. Supportive regulatory environments and established guidelines validate next generation sequencing applications, ensuring quality and reliability in clinical settings. Partnerships and collaborations between technology providers, pharmaceutical companies, and research institutions foster innovation, product development, and wider accessibility to NGS-based oncology tests.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of clinical oncology next generation sequencing. The growth and trends of clinical oncology next generation sequencing industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the clinical oncology next generation sequencing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing & Resequencing

By Workflow

  • NGS Pre-Sequencing
  • NGS Sequencing
  • NGS Data Analysis

By Application

  • Screening (Sporadic Cancer, Inherited Cancer)
  • Companion Diagnostics
  • Other Diagnostics

By End-Use

  • Hospitals
  • Clinics
  • Laboratories

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Oncology Next Generation Sequencing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Oncology Next Generation Sequencing market include Illumina Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd., Paradigm Diagnostics, Caris Life Sciences, Partek Inc., Eurofins Scientific S.E., Qiagen N.V. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Technology
    • 3.7.2 Market Attractiveness Analysis By Workflow
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY TECHNOLOGY

  • 5.1 Overview by Technology
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Technology
  • 5.4 Whole Genome Sequencing Historic and Forecast Sales by Regions
  • 5.5 Whole Exome Sequencing Historic and Forecast Sales by Regions
  • 5.6 Targeted Sequencing & Resequencing Historic and Forecast Sales by Regions

6 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY WORKFLOW

  • 6.1 Overview by Workflow
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Workflow
  • 6.4 NGS Pre-Sequencing Historic and Forecast Sales by Regions
  • 6.5 NGS Sequencing Historic and Forecast Sales by Regions
  • 6.6 NGS Data Analysis Historic and Forecast Sales by Regions

7 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Screening (Sporadic Cancer, Inherited Cancer) Historic and Forecast Sales by Regions
  • 7.5 Companion Diagnostics Historic and Forecast Sales by Regions
  • 7.6 Other Diagnostics Historic and Forecast Sales by Regions

8 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Hospitals Historic and Forecast Sales by Regions
  • 8.5 Clinics Historic and Forecast Sales by Regions
  • 8.6 Laboratories Historic and Forecast Sales by Regions

9 . GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. South East Asia Sales Analysis
    • 9.5.10. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING COMPANIES

  • 10.1. Clinical Oncology Next Generation Sequencing Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

  • 11.1. Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Illumina Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Thermo Fisher Scientific
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. F. Hoffmann-La Roche Ltd.
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Agilent Technologies
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Myriad Genetics
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Beijing Genomics Institute (BGI)
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Perkin Elmer
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Foundation Medicine
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Pacific Bioscience
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Oxford Nanopore Technologies Ltd.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Paradigm Diagnostics
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Caris Life Sciences
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Partek Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Eurofins Scientific S.E.
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Qiagen N.V.
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Analysis Market by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Clinical Oncology Next Generation Sequencing Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Clinical Oncology Next Generation Sequencing Report
  • Market Research Process
  • Market Research Methodology
  • Global Clinical Oncology Next Generation Sequencing Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Technology
  • Market Attractiveness Analysis by Workflow
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Technology (USD MN)
  • Whole Genome Sequencing Market Sales by Geography (USD MN)
  • Whole Exome Sequencing Market Sales by Geography (USD MN)
  • Targeted Sequencing & Resequencing Market Sales by Geography (USD MN)
  • Global Market Analysis by Workflow (USD MN)
  • NGS Pre-Sequencing Market Sales by Geography (USD MN)
  • NGS Sequencing Market Sales by Geography (USD MN)
  • NGS Data Analysis Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Screening (Sporadic Cancer, Inherited Cancer) Market Sales by Geography (USD MN)
  • Companion Diagnostics Market Sales by Geography (USD MN)
  • Other Diagnostics Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Clinics Market Sales by Geography (USD MN)
  • Laboratories Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.